SMI.London 2025 is the only event dedicated to Soft Mist Inhalers (SMIs) on this planet. YEP!
SMIs (Soft Mist Inhalers) are set to capture 50% of the portable inhaler market, valued for their efficiency, user-friendliness and versatility. The event will highlight the expanding role of SMIs amongst inhalation devices and the benefits they offer. Focusing particularly on biologic therapies, this one-day conference will delve into the regulatory and scientific aspects of SMI development, covering the journey from formulation design to finished dosage forms. Attendees can expect presentations from world leading experts in inhaled drug delivery, offering insights into the latest advancements and challenges in the field including:
- Daniela Traini, Woolcock Institute of Medical Research, Macquarie University and Ab Initio Pharma
Exploring Nasal siRNA-LNP SMI Therapies.
- Deborah Jones, Proveris Laboratories
Seeing Through The Mist: SMI Spray Characterization.
- William Ganley, Nanopharm, an Aptar Pharma company
Links Between Solution Properties, Spray & Lung Deposition In SMI.
- Philippe Rogueda, Merxin Ltd
Aerosolization Of Wegovy With MRX004 (SMI).
- Remi Rosiere, InhaTarget Therapeutics
LNPs and SMIs: Extending Formulation & Treatment Options.
- Laury Livemont, Unither Pharmaceuticals
Sterile Filling Of SMI Cartridges.
- Nicolas Buchmann, Resyca B.V.
Expanding The SMI World: Options & Applications.
- Marko Blom & Christian Walk, Micronit B.V.
Innovating Spray Nozzle Technology: How Microfluidic Manufacturing Drives Precision.
Don’t miss out. Come & shape the future of Inhalation Drug Delivery. Register today at www.smi.london to be a part of the conversation at SMI.London 2025. Early Bird Deadline: 25th April 2025.
